Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulation of mitochondrial biogenesis by the 5-HT1F receptor and its agonist in inferior spinal cords after spinal cord injury.

Neuroscience letters·2026
Same author

A biomimetic nano-platelet as an antidote for dual antiplatelet therapy-induced bleeding.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

An appropriate ASMI cutoff value enhances utilization of the CHARLS database for studying sarcopenia.

The journals of gerontology. Series A, Biological sciences and medical sciences·2026
Same author

YY1 Promotes Diabetic Vascular Calcification Via m<sup>6</sup>A-Binding Protein HNRNPC.

Free radical biology & medicine·2026
Same author

From Mechanism to Therapy: Establishing an Integrated Framework for the Regulation and Intervention of Matrix Vesicles in Vascular Calcification.

Cardiovascular drugs and therapy·2026
Same author

An Ultrasensitive Electrochemical Pepsin Immunosensor Based on Heterogeneous Ag@Co(OH)<sub>2</sub> NWs for Rapid Diagnostic Testing of Aspiration Pneumonia.

ACS applied materials & interfaces·2026

Related Experiment Video

Updated: Jun 27, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Advancements in Immune Checkpoint-Based Immunotherapy for Triple-Negative Breast Cancer.

Dexian Wei1,2, Yuan Zhang1, Yanlin Wu1

  • 1State Key Laboratory of Drug Regulatory Sciences, National Institutes for Food and Drug Control, Beijing 102629, China.

Current Issues in Molecular Biology
|June 26, 2026
PubMed
Summary

Triple-negative breast cancer (TNBC) immunotherapy shows promise. Immune checkpoint inhibitors (ICIs) and other novel strategies like CAR-T therapy offer new treatment avenues for this aggressive cancer.

Keywords:
immune checkpoint blockadeimmune checkpointsimmunotherapytriple-negative breast cancer

More Related Videos

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Related Experiment Videos

Last Updated: Jun 27, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype lacking ER, PR, and HER2 expression.
  • Current treatments like surgery and chemotherapy have limitations due to high recurrence and metastasis rates.

Purpose of the Study:

  • To review immune checkpoint-based immunotherapy for TNBC.
  • To explore mechanistic insights, clinical applications, and emerging strategies.

Main Methods:

  • Literature review focusing on immune checkpoint inhibitors (ICIs).
  • Discussion of alternative immunotherapies including bispecific antibodies, ADCs, CAR-T therapy, tumor vaccines, and oncolytic viruses (OVs).

Main Results:

  • Immune checkpoint inhibitors (ICIs) demonstrate clinical benefit, especially combined with chemotherapy for advanced TNBC.
  • Emerging strategies like CAR-T therapy and ADCs show potential in ongoing research and clinical trials.

Conclusions:

  • Immunotherapy, particularly ICIs, offers a promising new strategy for TNBC management.
  • Diverse immunotherapeutic approaches are advancing TNBC treatment, with ongoing research into their efficacy and application.